Lates News

Novo Nordisk rose 1% in early trading on Thursday. The company filed a lawsuit to block Hims & Hers from selling a combination of semaglutide, following hints from the US Food and Drug Administration and Department of Health and Human Services of possible enforcement action. Hims has temporarily suspended the supply of oral formulations, causing its stock price to drop 1.5% in early trading on Thursday.